Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : Regn save search
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
Published: 2024-02-21 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.54%
H: 0.63%
C: 0.09%
fda review treatment
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
Published: 2024-02-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
treatment ema
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -1.82%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.33%
H: 0.65%
C: -1.26%
dupixent fda first children approved year treatment
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -1.82%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.33%
H: 0.65%
C: -1.26%
dupixent fda first children approved year treatment
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.67 -0.04% 230K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
libtayo cell treatment
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Published: 2023-10-03 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: -0.74%
H: 0.21%
C: -0.45%
NTLA | $20.99 -1.55% 560K
|
Health Technology
|
| O: -0.1%
H: 1.97%
C: 1.02%
treatment research collaboration neurological
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
Published: 2023-09-29 (Crawled : 13:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 1.64%
H: 0.04%
C: -0.57%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: -0.13%
H: 0.02%
C: -1.26%
fda review treatment
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
dupixent fda children review treatment
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
dupixent fda children review treatment
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Published: 2023-09-25 (Crawled : 21:00) - globenewswire.com
RARE F | $41.575 -4.16% 370K
|
Health Technology
|
| O: 0.46%
H: 4.26%
C: 1.55%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
evkeeza treatment hypercholesterolemia canada
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
Published: 2023-08-23 (Crawled : 14:00) - biospace.com/
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.52%
H: 0.3%
C: -0.5%
disease treatment
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
Published: 2023-08-18 (Crawled : 23:00) - globenewswire.com
REGN | $893.67 -0.04% 230K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
| Email alert
Add to watchlist
fda eylea macular approved treatment injection diabetic
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
Published: 2023-08-18 (Crawled : 18:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.52%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: -0.39%
H: 3.29%
C: 2.21%
fda disease children approval treatment
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Published: 2023-08-17 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 2.95%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: -0.91%
H: 0.0%
C: 0.0%
treatment ema
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Published: 2023-03-29 (Crawled : 12:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.37%
H: 0.6%
C: -1.28%
libtayo lung approved positive cancer cell treatment
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
Published: 2023-03-07 (Crawled : 07:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.21%
H: 0.2%
C: -1.04%
dupixent treatment fda urticaria application review
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
Published: 2023-03-07 (Crawled : 07:00) - biospace.com/
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.21%
H: 0.2%
C: -1.04%
dupixent treatment fda urticaria application review
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Published: 2023-02-24 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -2.11%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: -0.77%
H: 1.52%
C: 0.42%
libtayo treatment lung chmp positive cancer
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.